WARMINSTER, Pa., November 13, 2025 — Leads & Copy — Arbutus Biopharma Corporation (Nasdaq: ABUS) today reported its third-quarter 2025 financial results and provided a corporate update, highlighting a strong financial position and progress in its clinical and intellectual property efforts.
The company’s cash, cash equivalents, and marketable securities totaled $93.7 million as of September 30, 2025. Key developments include an upcoming U.S. trial in March 2026 for the Moderna litigation and a favorable claim construction ruling in the Pfizer-BioNTech litigation from September 2025.
Arbutus is focused on its intellectual property, particularly concerning its LNP (Lipid Nanoparticle) technology, which is central to ongoing lawsuits against Moderna and Pfizer/BioNTech. These lawsuits aim to secure compensation for the use of Arbutus’s patented technology. The company, along with its exclusive licensee, Genevant Sciences, filed five international lawsuits against Moderna in March 2025, seeking to enforce patents across 30 countries. Public oral hearings for two of these cases are scheduled for May 2026, and a trial in the Canadian case is slated for September 2027.
In addition to intellectual property updates, Arbutus shared further analysis of clinical data for imdusiran (AB-729), which is being developed for chronic hepatitis B (HBV). Results showed that 46% of Phase 2a patients met the criteria to discontinue all treatment, and 94% of long-term follow-up patients remained off treatment for up to two years. Additionally, all HBV DNA positive patients in Phase 1b achieved HBV DNA levels below quantification after 18 weeks of imdusiran and nucleos(t)ide analogue therapy, with all HBV e-antigen positive patients demonstrating dose-dependent HBV e-antigen decreases.
Lindsay Androski, President and CEO of Arbutus, noted that the company remains dedicated to accelerating the development and potential approval of imdusiran. The company presented data from its HBV programs at AASLD 2025, including new analysis from the IM-PROVE I Phase 2a clinical trial, and had a Poster of Distinction highlighting AB-101’s maximal PD-L1 receptor occupancy.
Financial results for the third quarter 2025 include total revenue of $0.5 million, a research and development expense of $5.8 million, and a net loss of $7.7 million, or $0.04 per share. As of September 30, 2025, Arbutus had 192.0 million common shares outstanding, along with 14.9 million stock options and unvested restricted stock units.
Operating expenses decreased due to cost-saving measures, including streamlining the organization and discontinuing the IM-PROVE III clinical trial.
For investor inquiries, please use the contact details provided by Arbutus Biopharma Corporation.
Source: Arbutus Biopharma Corporation
